) announced encouraging results from a phase IIb study (n=354) on
bococizumab (RN316) being developed for the treatment of adults
suffering from high cholesterol and also taking statin therapy.
The study randomized patients with either bococizumab (twice or
once monthly subcutaneous administration) or placebo.
Results revealed that bococizumab showed significant reduction in
low density lipoprotein cholesterol (LDL-C) from baseline in
comparison to placebo in statin treated adults with high
cholesterol. The highest reductions in LDL-C were observed in 150
mg for the twice monthly regimen and 300 mg for the once monthly
regimen of bococizumab.
We are encouraged by the positive results from the phase IIb
study on bococizumab. The candidate is currently in a phase III
program, initiated in Oct 2013. Pfizer's phase III program on
bococizumab includes two cardiovascular outcome studies and
multiple lipid-lowering studies. Pfizer enrolled over 22,000
patients for the studies.
We believe successful development and subsequent
commercialization of bococizumab will strengthen Pfizer's
cardiovascular portfolio. Meanwhile, companies like
) are developing candidates for treating patients with high
Of late Pfizer has reported several encouraging results from its
late stage candidates. Pfizer will be hit by a series of patent
expiries including Aricept, Revatio and Viagra until 2015.
Successful developments of these late stage candidates are hence
important for the company to offset the loss.
Pfizer carries a Zacks Rank #3 (Hold). Investors looking for
better-ranked stocks in the medical sector may consider companies
), which carries a Zacks Rank #1 (Strong Buy).
ALKERMES INC (ALKS): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.